Univec, Inc. (UNVC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -1 | -1 | ||||||
| Net profit | $m | -1 | -1 | -3 | -3 | -1 | -1 | -1 | - |
| EPS reported | $ | 0.00 | 0.00 | ||||||
| Operating cashflow per share | $ | -0.01 | -0.01 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.01 | -0.01 | ||||||
| Free cash flow | $m | -16 | -16 | ||||||
| Net debt | $m | 1 | 1 | ||||||
| Book value equity | $m | -18 | -18 | ||||||
| Book value per share | $ | -0.01 | -0.01 | ||||||
| Number of shares | m | 2,523.1 | 2,523.1 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 5.00 | 10.00 | ||||||
| P/B LTM | x | -0.36 | -0.34 | ||||||
| P/S LTM | x | 74.20 | 69.19 | ||||||
| P/FCF LTM | x | -0.41 | -0.41 | ||||||
| EV/EBITDA LTM | x | -6.48 | -6.10 | ||||||
| EV/Sales LTM | x | 91.20 | 93.96 | ||||||
| Earnings Yield LTM | % | +20.00% | +10.00% | ||||||
| FCF Yield | % | -246.54% | -246.59% | ||||||
| Quality | |||||||||
| ROE | % | +6.87% | +6.94% | ||||||
| ROIC | % | +7.40% | +7.67% | ||||||
| Operating margin | % | -14.15% | -14.42% | ||||||
| Gross margin | % | +9.48% | +13.66% | ||||||
| FCF/Sales | % | -18292.6% | -17667.2% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +130.97% | +147.67% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -10.76 | -10.56 | ||||||
| Net Debt/EBITDA | x | -1.21 | -1.15 | ||||||
| EBIT/Net interest | x | -98.14 | -57.94 | ||||||
| Net debt/market cap | % | +22.92% | +21.39% | ||||||
| Net debt/Equity | x | -0.08 | -0.08 | ||||||
| Gross debt/equity | x | -0.08 | -0.08 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Univec, Inc. is a medical device firm that, through its various operating divisions, develops, licenses, and sells products across the United States and internationally. Its primary offerings include a range of auto-disable and safety syringes. These encompass 1cc AD-syringes, which can be used for both aspirating and non-aspirating procedures, typically for dispensing precise doses of allergy, immunization, and insulin medications. Univec also produces sliding sheath syringes, engineered to protect both patients and healthcare professionals from accidental needlestick injuries. Additionally, the company manufactures bifurcated needle safety syringes, specifically designed for administering smallpox vaccines, particularly in response to potential bioterrorist threats. Univec distributes its auto-disable and sliding sheath safety syringes to private hospitals, other healthcare facilities, and distributors within the U.S., as well as to governmental entities in developing countries. Furthermore, it offers an online system that assists pharmaceutical companies with the marketing, fulfillment, and tracking of drug samples, serving as a connector between pharmacies and managed payment providers. The company was founded in 1992 and is based in Baltimore, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Univec, Inc. is a medical device firm that, through its various operating divisions, develops, licenses, and sells products across the United States and internationally. Its primary offerings include a range of auto-disable and safety syringes. These encompass 1cc AD-syringes, which can be used for both aspirating and non-aspirating procedures, typically for dispensing precise doses of allergy, immunization, and insulin medications. Univec also produces sliding sheath syringes, engineered to protect both patients and healthcare professionals from accidental needlestick injuries. Additionally, the company manufactures bifurcated needle safety syringes, specifically designed for administering smallpox vaccines, particularly in response to potential bioterrorist threats. Univec distributes its auto-disable and sliding sheath safety syringes to private hospitals, other healthcare facilities, and distributors within the U.S., as well as to governmental entities in developing countries. Furthermore, it offers an online system that assists pharmaceutical companies with the marketing, fulfillment, and tracking of drug samples, serving as a connector between pharmacies and managed payment providers. The company was founded in 1992 and is based in Baltimore, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free